CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges

por Harrer, Dennis C., Dörrie, Jan, Schaft, Niels
Publicado 2019

CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia

por Harrer, Dennis C., Schuler, Gerold, Dörrie, Jan, Schaft, Niels
Publicado 2019

Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer

por Simon, Bianca, Harrer, Dennis C., Schuler-Thurner, Beatrice, Schuler, Gerold, Uslu, Ugur
Publicado 2019

Continuous Complete Remission in Two Patients with Acute Lymphoblastic Leukemia and Severe Fungal Infection Following Short-Term, Dose-Reduced Chemotherapy

por Lüke, Florian, Harrer, Dennis C., Hahn, Joachim, Grube, Matthias, Pukrop, Tobias, Herr, Wolfgang, Reichle, Albrecht, Heudobler, Daniel
Publicado 2021

All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma

por Fante, Matthias A., Harrer, Dennis C., Zartner, Barbara, Lüke, Florian, Mayer, Stephanie, Menhart, Karin, Reichle, Albrecht, Herr, Wolfgang, Vogelhuber, Martin, Heudobler, Daniel
Publicado 2023

RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melan...

por Harrer, Dennis C., Simon, Bianca, Fujii, Shin-ichiro, Shimizu, Kanako, Uslu, Ugur, Schuler, Gerold, Gerer, Kerstin F., Hoyer, Stefanie, Dörrie, Jan, Schaft, Niels
Publicado 2017

Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease

por Lüke, Florian, Harrer, Dennis C., Menhart, Karin, Wolff, Daniel, Holler, Ernst, Hellwig, Dirk, Herr, Wolfgang, Grube, Matthias, Vogelhuber, Martin, Reichle, Albrecht, Heudobler, Daniel
Publicado 2021